Welcome to The Short Read, our weekly peek behind the curtain at the people who make this amazing community tick. Make sure to check back every Tuesday for the latest installment.

Nikolai Slavov, PhD, Assistant Professor, Bioengineering, Northeastern University
Nikolai Slavov received his undergraduate degree from MIT in 2004, then pursued doctoral research in the Botstein laboratory, aiming to understand how cells coordinate their growth, gene expression, and metabolism. There, he and his team discovered a simple mechanism that can account for the growth-rate dependent transcriptional responses across a wide range of growth conditions and growth rates. Following this, Nikolai began a postdoctoral project in the van Oudenaarden laboratory at MIT, aiming to understand aerobic glycosis, also known as Warburg effect, which is a hallmark of cancer cells associated with respiratory metabolism and stress survival.
Nikolai is excited about sharing new methods and results from his laboratory as well as finding synergistic collaborations at this year’s Festival of Genomics Boston, as well as discussing how results may advance translational research in biotech. He will be a loop leader in one of our new session formats ‘In the Loop’ on day one, entitled ‘Building a holistic vision of a single cell’. He will also be presenting on Horizon Stage 1 on day two with his presentation ‘Mass-spectometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation’.
What are you working on right now?
In terms of technology development, we are evolving our approach to Single Cell ProtEomics by Mass Spectrometry (SCoPE-MS) to significantly enhance the throughput and the accuracy of quantifying thousands of proteins in single mammalian cells. We are also building upon and extending our ideas to enable quantifying post-translational modifications in single cells. These new types of data have motivated us to think about the conceptual framework within which we can understand them and apply them to exciting biological problems, such as understanding signalling heterogeneity during directed cell differentiation and cancer metastasises. My laboratory is also actively working on understanding how ribosome modifications contribute to regulating protein synthesis (Slavov et al., 2015). I am very excited by all of these projects, especially by thinking of new ways for understanding single-cell proteomics data and new principles behind ribosome-mediated translational regulation.
What’s the biggest challenge your research field faces at the moment?
The biggest challenge is coming up with a creative conceptual idea. This is well illustrated with the development of Single Cell ProtEomics by Mass Spectrometry (SCoPE-MS). SCoPE-MS could have been developed seven years ago if a PI had the idea for it; in fact, we developed SCoPE-MS using only technology that was already present in 2010, and awaited the idea that would enable single-cell proteomics by mass-spectrometry. Now that the idea had been demonstrated, the major mass-spectrometry labs around the world are actively building upon it, using the latest technologies. What was rate limiting was the idea – not the technology.
I think that the promising ideas that can enable both new technologies and conceptual breakthroughs outnumber the people who think creatively enough to realize them. In my research area, this is due in part because relatively few biologists understand mass-spectrometry deeply enough to apply it in creative ways to exciting biological problems. More broadly, the development of new ideas is hampered by an excessive emphasis on data generation. The community and the granting agencies reward tangible results, which are mostly easily and speedily produced by applying new cutting-edge technologies to generate large datasets rather than by developing and demonstrating new concepts. I think the progress of biomedical research will be much accelerated if we find a way to reward more conceptual advances and ideas and deemphasize mere data generation.
Name one big development that you would like to see in your field the next 18 months.
I would like to see more emphasis on understanding data rather than merely generating them.
What are you most proud of in your career?
The work I am most proud of is not my best-known work. As a graduate student, I was enthralled by a mysterious phenomenon of emergent cell synchrony that indicated partial coupling between metabolism and cell division. I started working on this project accepting the suggested hypotheses in the field, e.g., that DNA replication has to be sequestered to a reductive metabolic phase, and designing experiments that seemed logical. The experiments worked very differently from expected, and I constantly had to readjust both my conceptual framework and experimental approach. Finally, we discovered that DNA replication is not incompatible with respiration and that hundreds of mRNAs annotated to cell division are expressed periodically even when cells do not divide (Slavov and Botstein, 2011, Slavov et al., 2011). I am proud of these results because they required willingness to confront and radically reshape preconceptions based on experiments that allowed for very clean conclusions. Furthermore, I felt (and still feel) that we were among the few people who could have done this research, and thus we could make a non-redundant contribution.
Which scientists, living, dead, or fictional, would you invite to dinner, and why?
I would invite Hans Bethe, Richard Feynman, and Julian Schwinger. These scientists were brilliant but their brilliance appears quite different, and I would love to see the dynamics of their interactions. Also, I would love to have dinner with Michael S. Brown and Joseph L. Goldstein to see the interactions in such a great team.
What advice do you wish someone had given you at the start of your career?
Young scientists can best advance their career by working on very important and promising problems for which they have strong aptitude and which can be appreciated by the contemporaneously by mainstream community. I have always had the tendency to ignore the last part, the contemporaneous appreciation, and be partial to ideas that I think are visionary and by implication hard to understand and appreciated contemporaneously by everybody. Yet, building a career requires that at least some of the work of a young scientist can be easily understood and appreciated contemporaneously by the mainstream community
Opinions and views expressed in The Short Read are the interviewee’s and not those of the home institution
Why not check out The Short Read archives?
George Church
|
|
Amalio Telenti
|
|
Anna Middleton
|
|
Nan Doyle
|
|
David Smith
|
|
Hannes Smárason
|
|
Eric Topol
|
|
Kristen Sund
|
|
Manuel Corpas
|
|
Brendan Gallagher
|
|
Hayley Robinson
|
|
Valentina Nardi
|
|
Stephen Kingsmore
|
|
Judith Benkendorf
|
|
David Flannery
|
|
Sarah Teichmann
|
|
T. Patrick Hill
|
|
Liz Harley
|
|
Nick Lench
|
|
Carlos Bustamante
|
|
Paula Goldenberg
|
|
Said Ismail
|
|
James Christensen
|
|
Enrique Velazquez
|
|
Damien Tully
|
|
Nazneen Rahman
|
|
Kazuharu Arakawa“Don’t Get Too Caught Up With Secondary Findings” |
|
Nan Fang“Bioinformatics has Become Vital to Make Sense of All Sequencing Data” |
|
Robert Green“Pick the Right Controversy” |
|
Carl Smith“It’s Okay to Ask ‘Stupid’ Questions” |
|
Luke Timmerman“But No Question, I’m Going Against the Grain of Consumer Expectations” |
|
Hans Cobben“Young Scientists and Entrepreneurs Really Should Not be Afraid to Boldly Venture in Uncharted Territory” |
|
Angela Kaczmarczyk“I’d Love to See More Community Labs and Biohackers Publish Their Projects in Open-Access Journals” |
|
Justin O’Grady“There is no Substitute for Hard Work” |
|
Dale Yuzuki“It’s True that the ‘Century of Biology’ is Now” |
![]() |
Enoch Huang“To Go Fast, Go Alone, to Go Far, Go Together” |
![]() |
Who would you like to see interviewed for The Short Read? Let us know via contact@frontlinegenomics.com